Back to search
FDAFDA · Food and drugs·Recall number D-0466-2024

Abilify (aripiprazole), 5 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-007-13

Published May 1, 2024 · Recall initiated: April 9, 2024

Summary

FDA records drug Class III recall D-0466-2024, published May 1, 2024 and initiated April 9, 2024. Recalling firm: Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.; Status: Ongoing; Reported quantity: 108,192/30 count bottles or 7 count blister packs; Lot: Lot # AKS00623A, Exp 01/31/2026; AKS00322A, Exp 02/28/2025. Class III means the product is not likely to cause adverse health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Cross Contamination with Other Products

What to do

Voluntary: Firm initiated · Letter

Get an email if ABILIFY has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
ABILIFY
Manufacturer
Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
Distributor
USA nationwide.
Lot
Lot # AKS00623A, Exp 01/31/2026; AKS00322A, Exp 02/28/2025
Risk classification
Class III
Area (FDA)
drug
Country
Japan

Related recalls

Questions about this recall

Was Abilify (aripiprazole), 5 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-007-13 recalled?

Yes. FDA published recall D-0466-2024 on May 1, 2024. Reported hazard: Cross Contamination with Other Products

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: ABILIFY.